Glutaric B-Disease
acidemias I-Disease
comprise I-Disease
different I-Disease
disorders I-Disease
resulting O
in O
an O
increased O
urinary O
excretion O
of O
glutaric O
acid. O
Glutaric O
acidemia O
type I-Chemical
1 I-Chemical
(GA-1) O
is I-Disease
an I-Disease
autosomal I-Disease
recessive I-Disease
disorder O
of I-Disease
lysine, I-Disease
hydroxylysine, I-Disease
and O
tryptophan I-Chemical
metabolism I-Chemical
caused O
by I-Chemical
deficiency I-Chemical
of O
glutaryl-CoA O
dehydrogenase. I-Disease
It I-Disease
results I-Disease
in I-Disease
the I-Disease
accumulation I-Disease
of O
3-hydroxyglutaric O
and O
glutaric O
acid. I-Chemical
Affected I-Chemical
patients I-Chemical
can I-Chemical
present I-Chemical
with O
brain B-Species
atrophy I-Species
and O
macrocephaly O
and I-Disease
with I-Disease
acute O
dystonia I-Disease
secondary I-Disease
to O
striatal O
degeneration I-Disease
in O
most O
cases I-Disease
triggered I-Disease
by I-Disease
an O
intercurrent O
childhood O
infection O
with O
fever O
between O
6 I-Disease
and I-Disease
18 O
months O
of I-Disease
age. O
This O
disorder O
can O
be O
identified O
by O
increased O
glutaryl O
(C5DC) O
carnitine O
on B-Chemical
newborn I-Chemical
screening. I-Chemical
Urine I-Chemical
organic O
acid O
analysis O
indicates O
the I-Chemical
presence I-Chemical
of O
excess O
3-OH-glutaric O
acid, O
and O
urine O
acylcarnitine I-Chemical
profile O
shows O
glutaryl I-Chemical
carnitine I-Chemical
as O
the O
major B-Chemical
peak. I-Chemical
Therapy I-Chemical
consists O
in O
carnitine O
supplementation O
to B-Chemical
remove I-Chemical
glutaric O
acid, O
a O
diet O
restricted O
in I-Chemical
amino I-Chemical
acids O
capable O
of O
producing O
glutaric O
acid, O
and O
prompt O
treatment B-Chemical
of I-Chemical
intercurrent O
illnesses. O
Early O
diagnosis O
and O
therapy O
reduce O
the O
risk O
of O
acute O
dystonia O
in O
patients O
with O
GA-1. B-Disease